Monte Rosa Therapeutics, Inc. (GLUE) Revenue History
Annual and quarterly revenue from 2019 to present
GLUE Revenue Over Time (2019–2025)
GLUE Revenue Growth History
1 of 1 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +63.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $4.2M | -95.0% |
| Q4 2025 | $2.8M | -95.4% |
| Q3 2025 | $12.8M | +38.5% |
| Q2 2025 | $23.2M | +394.0% |
| Q1 2025 | $84.9M | +7882.0% |
| Q4 2024 | $60.6M | — |
| Q3 2024 | $9.2M | — |
| Q2 2024 | $4.7M | — |
Multi-year avg. share of annual revenue by fiscal quarter
GLUE Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 12, 2026, Monte Rosa Therapeutics, Inc. (GLUE) generated trailing twelve-month (TTM) revenue of $43.0 million, reflecting significant decline in growth of -95.0% year-over-year. The most recent quarter (Q1 2026) recorded $4.2 million in revenue, up 51.4% sequentially.
Historical Growth Trajectory
GLUE's historical revenue data shows various trends over time. Monte Rosa Therapeutics, Inc.'s highest annual revenue of $123.7 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including ARVN (-79.1% YoY), KYMR (-12.6% YoY), and VRTX (+10.4% YoY) — GLUE has underperformed the peer group in revenue growth. Compare GLUE vs ARVN →
GLUE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 GLUECurrent | $43M | -95.0% | - | -43.8% | |
 ARVN | $263M | -79.1% | +58.9% | -43.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
GLUE Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $123.7M | +63.5% | $115.3M | 93.2% | $-54,208,000 | -43.8% |
| 2024 | $75.6M | - | $67.5M | 89.3% | $-81,112,000 | -107.3% |
| 2023 | $0 | - | $-6,222,000 | - | $-143,311,000 | - |
| 2022 | $0 | - | $0 | - | $-112,384,000 | - |
| 2021 | $0 | - | $0 | - | $-72,882,000 | - |
| 2020 | $0 | - | $-537,000 | - | $-28,010,000 | - |
| 2019 | $0 | - | $-72,000 | - | $-7,994,000 | - |
What if you invested $1,000 in GLUE back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in GLUE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GLUE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGLUE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowGLUE — Frequently Asked Questions
Quick answers to the most common questions about buying GLUE stock.
Is GLUE's revenue growth accelerating or slowing?
GLUE revenue is declining -95.0% year-over-year. TTM revenue fell to $43M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is GLUE's revenue history from 2019 to 2026?
Monte Rosa Therapeutics, Inc. (GLUE) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $43M, growing at -95.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is GLUE's long-term revenue growth rate (CAGR)?
Monte Rosa Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -95.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for GLUE.
Why does GLUE's quarterly revenue fluctuate?
GLUE quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Monte Rosa Therapeutics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is GLUE's revenue distributed by segment?
GLUE reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does GLUE's revenue compare to industry peers?
Monte Rosa Therapeutics, Inc. (GLUE) with TTM revenue of $43M and -95.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.